Cytokine fusion protein treatment.

Abstract

Mice suffering from melanoma can be cured by treatment with a recombinant antibody-lymphotoxin-alpha fusion protein. In order to characterize the involvement of T cells in this syngeneic tumor model, the T cell receptor repertoire was analyzed both quantitatively and qualitatively. In this connection, quantitative analysis of the T cell receptors displayed only a modest overexpression in some of the variable beta chain families over the course of therapy. Clonotypic mapping, however, revealed a marked increase in the number of clonally expanded T cells among the tumor-infiltrating T cells, suggesting a specific activation.

• Authors: David Schrama, Per thor Straten, Eva-Bettina Bröcker, Ralph A Reisfeld, Jürgen C Becker
• Journal: Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer (Recent Results Cancer Res) Vol. 160 Pg. 185-94 ( 2002) ISSN: 0080-0015 [Print] Germany
• PMID: 12079213 (Publication Type: Journal Article)

Chemical References

• Cytokines
• Lymphotoxin-alpha
• Recombinant Fusion Proteins

Topics

• Animals
• Clone Cells
• Cytokines (therapeutic use)
• Lymphotoxin-alpha (therapeutic use)
• Melanoma, Experimental (therapy)
• Mice
• Mice, Inbred C57BL
• Recombinant Fusion Proteins (therapeutic use)
• Reverse Transcriptase Polymerase Chain Reaction
• T-Lymphocytes (immunology)
• Tumor Cells, Cultured